PMID- 35129829
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 2509-4254 (Electronic)
IS  - 2509-4262 (Print)
IS  - 2509-4262 (Linking)
VI  - 6
IP  - 3
DP  - 2022 May
TI  - Health State Utilities for Adverse Events Associated with Chimeric Antigen 
      Receptor T-Cell Therapy in Large B-Cell Lymphoma.
PG  - 367-376
LID - 10.1007/s41669-021-00316-0 [doi]
AB  - BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy provides effective 
      treatment for large B-cell lymphoma (LBCL). Cost-utility analyses examining and 
      comparing the value of these treatments require health state utilities 
      representing key characteristics to differentiate among therapies. This study 
      estimated utilities for adverse events (AEs) associated with CAR T-cell therapy, 
      including cytokine release syndrome (CRS) and neurological events (NEs). METHODS: 
      Health state vignettes were drafted based on literature review, AE reports from a 
      trial of CAR T-cell therapy, and clinician input. Health states were valued in 
      time trade-off interviews with general population participants in the UK. The 
      first vignette described relapsed/refractory LBCL treated with CAR T-cell therapy 
      without AEs. Five other vignettes had the same LBCL and treatment description, 
      with the addition of an AE. Disutilities (i.e., utility decrease) associated with 
      these AEs were calculated by subtracting the utility of the health state without 
      AEs from those of the other health states. RESULTS: Interviews were completed 
      with 218 participants (50% male; mean age 49 years). Mean (standard deviation 
      [SD]) utility for CAR T-cell therapy without AEs was 0.73 (0.30). Mean (SD) 
      disutilities associated with CRS were -0.01 (0.04) for grade 1, -0.05 (0.09) for 
      grade 2, and -0.23 (0.24) for grade 3/4. Mean (SD) disutilities associated with 
      NEs were -0.04 (0.07) for grade 1/2 and -0.18 (0.22) for grade 3/4. CONCLUSIONS: 
      More severe AEs were associated with greater disutilities. Health state utilities 
      estimated in this study may be useful in cost-effectiveness models examining the 
      value of CAR T-cell therapy in patients with LBCL.
CI  - (c) 2022. The Author(s).
FAU - Howell, Timothy A
AU  - Howell TA
AD  - Patient-Centered Research, Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, 
      MD, 20814, USA.
FAU - Matza, Louis S
AU  - Matza LS
AUID- ORCID: 0000-0001-6374-5948
AD  - Patient-Centered Research, Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, 
      MD, 20814, USA. louis.matza@evidera.com.
FAU - Jun, Monika P
AU  - Jun MP
AD  - Bristol Myers Squibb, Princeton, NJ, USA.
FAU - Garcia, Jacob
AU  - Garcia J
AD  - Bristol Myers Squibb, Seattle, WA, USA.
FAU - Powers, Annette
AU  - Powers A
AD  - Bristol Myers Squibb, Princeton, NJ, USA.
FAU - Maloney, David G
AU  - Maloney DG
AD  - Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 
      USA.
LA  - eng
PT  - Journal Article
DEP - 20220207
PL  - Switzerland
TA  - Pharmacoecon Open
JT  - PharmacoEconomics - open
JID - 101700780
PMC - PMC9043043
COIS- Timothy A. Howell and Louis S. Matza are employees of Evidera, which received 
      funding from Bristol Myers Squibb to conduct the analyses. Monika P. Jun and 
      Annette Powers are employees of Bristol Myers Squibb and hold stock in Bristol 
      Myers Squibb. Jacob Garcia was an employee of Bristol Myers Squibb when the work 
      reported in this manuscript was conducted and holds stock in Bristol Myers 
      Squibb. His current affiliation is Umoja Biopharma, Seattle, WA, USA. David G. 
      Maloney has received consultancy fees and honoraria from A2 Biotherapeutics, 
      Amgen, BioLineRx, Celgene (a Bristol Myers Squibb Company), Genentech, Gilead 
      Sciences, Juno Therapeutics (a Bristol Myers Squibb Company), Kite Pharma (a 
      Gilead Company), MorphoSys, Novartis, and Pharmacyclics, and grants for research 
      from Celgene (a Bristol Myers Squibb Company), Juno Therapeutics (a Bristol Myers 
      Squibb Company), and Kite Pharma (a Gilead Company).
EDAT- 2022/02/08 06:00
MHDA- 2022/02/08 06:01
PMCR- 2022/02/07
CRDT- 2022/02/07 12:16
PHST- 2021/11/30 00:00 [accepted]
PHST- 2022/02/08 06:00 [pubmed]
PHST- 2022/02/08 06:01 [medline]
PHST- 2022/02/07 12:16 [entrez]
PHST- 2022/02/07 00:00 [pmc-release]
AID - 10.1007/s41669-021-00316-0 [pii]
AID - 316 [pii]
AID - 10.1007/s41669-021-00316-0 [doi]
PST - ppublish
SO  - Pharmacoecon Open. 2022 May;6(3):367-376. doi: 10.1007/s41669-021-00316-0. Epub 
      2022 Feb 7.